LUND, Sweden, June 4, 2019 /PRNewswire/ -- Camurus announces that the leading drug dependence journal Addiction has today published full results from a 48-week, open-label, global Phase 3 study of ...

Camurus (NASDAQ: CAMX) (STO: CAMX) today announced positive, final, topline results from the 52-week Phase 3 open-label ACROINNOVA 2 (NCT04125836) study, which evaluated safety and efficacy of the ...

Camurus (NASDAQ STO: CAMX) today announced topline results from the 12-month, randomized, double-blind, placebo-controlled POSITANO Phase 2b study (NCT05281328), evaluating efficacy and safety of ...

Camurus AB (STO:CAMX) presented its first quarter 2025 results on May 15, revealing strong financial performance despite challenging market conditions. The Swedish biopharmaceutical company, which ...

(RTTNews) - Camurus (CAMX), Friday announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending market authorization of ...

Camurus eligible to receive up to $870 million in potential development and sales milestone payments and mid-single-digit royalty "We are pleased to enter into this collaboration with Lilly to ...

Camurus AB will release earnings for the most recent quarter on May 12.Analysts are expecting losses per share of SEK 0.219.Go here to follow Camu ...

If approved, it could be available as early as March. Braeburn Pharmaceuticals Inc. and Camurus AB on Thursday, July 20 submitted their new drug application to the U.S. Food and Drug ...

Rhythm will use Camurus' drug delivery technology, FluidCrystal ®, to formulate its once-weekly obesity drug candidate, setmelanotide (RM-493), then develop, manufacture, and commercialize the ...

--Camurus today announced positive, final, topline results from the 52- week Phase 3 open-label ACROINNOVA 2 study, which evaluated safety and efficacy of the company's once-monthly octreotide ...

CAM2029 reduces liver and cyst volume growth compared to placebo Well tolerated with no new or unexpected safety findingsA follow-up Phase 3 study will be discussed with regulatory authoritiesLUND ...

Camurus maintained its full-year 2025 guidance, projecting revenue between SEK 2.7-3.0 billion (45-61% growth versus 2024) and profit before tax of SEK 0.9-1.2 billion (63-117% growth versus 2024).